Product Description
An investigational RNAi therapeutic targeting β-catenin for the treatment of HCC. The Wnt/β-catenin pathway is implicated in many human cancers, including HCC, a leading cause of cancer death worldwide. ALN-BCAT employs Alnylam’s advanced lipid nanoparticle (LNP) delivery technology termed “reLNP,” which provides improved tolerability due to enhanced biodegradability. (Sourced from: https://investors.alnylam.com/press-release?id=27841)
Mechanisms of Action: Wnt Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alnylam
Company Location: CAMBRIDGE MA 02142
Company CEO: Yvonne L. Greenstreet
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|